Update and review: State-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation

Transplantation Proceedings

Volumn 43, Issue 3 SUPPL., 2011, Pages

  Snydman, David R ^a,b   Limaye, Ajit P ^c   Potena, Luciano ^d   Zamora, Martin R ^e   Weigand, Kay ^f  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; CIDOFOVIR; CORTICOSTEROID; CYTOMEGALOVIRUS ANTIBODY; EVEROLIMUS; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BONE MARROW TOXICITY; BRONCHIOLITIS OBLITERANS; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; GRAFT RECIPIENT; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; NEPHROTOXICITY; PATIENT COMPLIANCE; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL; VIRUS REPLICATION;

EID: 79953864833     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.02.069     Document Type: Article

References (70)

1. A.J. Eid, and R.R. Razonable New developments in the management of cytomegalovirus infection after solid organ transplantation Drugs 70 2010 965
2. J.A. Fishman, V.C. Emery, and R. Freeman Cytomegalovirus in transplantation challenging the status quo Clin Transplant 21 2007 149
3. A. Humar, and D. Snydman and the AST Infectious Diseases Community of Practice: Cytomegalovirus in solid organ transplant recipients Am J Transplant 9 2009 S78
4. L.M. McDevitt Etiology and impact of cytomegalovirus disease on solid organ transplant recipients Am J Health Syst Pharm 63 2006 S3
5. V. Kliem, L. Fricke, and T. Wollbrink Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial Am J Transplant 8 2008 975
6. C.N. Kotton, and J.A. Fishman Viral infection in the renal transplant recipient J Am Soc Nephrol 16 2005 1758
7. I.G. Sia, and R. Patel New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients Clin Microbiol Rev 13 2000 83
8. T. Reischig, P. Jindra, and M. Svecova The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection J Clin Virol 36 2006 146
9. R.R. Razonable Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients Am J Health-Syst Pharm 62 2005 S7
10. C.L. Vinnard, and E.A. Blumberg Infections in Medicine http://infections.consultantlive.com/print/article/1145625 2008 Accessed: July 16, 2010
11. A.V. Cope, C. Sabin, and A. Burroughs Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation J Infect Dis 176 1997 1484
12. R.R. Razonable, C.V. Paya, and T.F. Smith Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients J Clin Microbiol 40 2002 746
13. C.N. Kotton, D. Kumar, and A.M. Caliendo International consensus guidelines on the management of cytomegalovirus in solid organ transplantation Transplantation 89 2010 779
14. American Society of Transplantation Cytomegalovirus Am J Transplant 4 2004 51
15. J.K. Preiksaitis, D.C. Brennan, J.A. Fishman, and U. Allen Canadian Society of Transplantation Consensus Workshop on cytomegalovirus management in solid organ transplantation final report Am J Transplant 5 2005 218
16. M.D. Pescovitz Antiviral therapies for cytomegalovirus in solid-organ transplantation Transplantation 84 2007 S2
17. G. Opelz, B. Dohler, and A. Ruhenstroth Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report Am J Transplant 4 2004 928
18. J.A. Khoury, G.A. Storch, and D.L. Bohl Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients Am J Transplant 6 2006 2134
19. A. Humar, A. Lebranchu, and F. Vincenti The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients Am J Transplant 10 2010 1228
20. S.M. Palmer, A.P. Limaye, and M. Banks Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial Ann Intern Med 152 2010 761
21. Valcyte {Prescribing Information} 2009 Genentech San Francisco CA
22. Cytogam {Prescribing Information} 2008 CSL Behring King of Prussia PA
23. N. Bonaros, B. Mayer, and T. Schachner CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis Clin Transplant 22 2008 89
24. Snydman DR: Presented at: ISHLT 30th Anniversary Meeting and Scientific Sessions; April 2124, 2010; Chicago, IL. Abstract 250224
25. Snydman DR: Presented at: American Transplant Congress; San Diego, CA; May 15, 2010. Abstract 989
26. Fisher R, Ulsh P: Presented at: American Transplant Congress; San Diego, CA; May 15, 2010. Abstract 251213
27. Fisher R, Ulsh P: Presented at: American Transplant Congress; San Diego, CA; May 15, 2010. Abstract 250246
28. A. Asberg, A. Humar, and H. Rollag Oral valganciclovir Is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients Am J Transplant 2007 2106 2113 (Pubitemid 47247057)
29. G. Boivin, N. Goyette, and C. Gilbert Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients J Infect Dis 189 2004 1615
30. A.J. Eid, S.K. Arthurs, and P.J. Deziel Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients Am J Transplant 157 2010
31. R.M. Kruger, W.D. Shannon, and M.Q. Arens The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation Transplantation 68 1999 1272
32. A.P. Limaye, G. Raghu, and D.M. Koelle High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy J Infect Dis 20 2002
33. N.S. Lurain, S.M. Bhorade, and K.J. Pursell Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients J Infect Dis 186 2002 760
34. F. Li, K.W. Kenyon, and K.A. Kirby Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients J Infect Dis 45 2007 439
35. A.P. Limaye Ganciclovir-resistant cytomegalovirus in organ transplant recipients Clin Infect Dis 35 2002 866
36. S.M. Bhorade, N.S. Lurain, and A. Jordan Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients J Heart Lung Transplant 21 2002 1274
37. F. Baldanti, N. Lurain, and G. Gerna Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs Hum Immunol 65 2004 403
38. S. Chou Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance Antimicrob Agents Chemother 2010 10.1128/AAC.00186-00110
39. C. Gilbert, and G. Boivin Human cytomegalovirus resistance to antiviral drugs Antimicrob Agents Chemother 49 2005 873
40. S. Chou, N.S. Lurain, and K.D. Thompson Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus J Infect Dis 188 2003 32
41. A.C. Kalil, J. Levitsky, and E. Lyden Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients Ann Intern Med 143 2005 870
42. L. Potena, C. Holweg, and M.L. Vana Frequent occult infection with cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis J Clin Microbiol 45 2007 1804
43. L. Potena, F. Grigioni, and G. Magnani Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients J Heart Lung Transplant 28 2009 461
44. T.C. Merigan, D.G. Renlund, and S. Keay A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation N Engl J Med 326 1992 1182 1186.
45. S. Sagedal, A. Hartmann, and K.P. Nordal Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival Kidney Int 66 2004 329
46. L. Potena, F. Grigioni, and P. Ortolani Revelance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three dimensional intravascular ultrasound study Transplantation 78 2003 839
47. Patel J: Presented at ISHLT 30th Anniversary Meeting and Scientific Sessions; April 2124, 2010; Chicago, IL. Abstract 372
48. H.A. Valantine The role of viruses in cardiac allograft vasculopathy Am J Transplant 4 2003 169
49. T. Compton, E.A. Kurt-Jones, and K.W. Boehme Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2 J Virol 77 2003 4588
50. F.R. Stassen, X. Vega-Crdova, I. Vliegen, and C.A. Bruggeman Immune activation following cytomegalovirus infection: more important than direct viral effects in cardiovascular disease? J Clin Virol 35 2006 349
51. C.H. Cook, A.A. Bickerstaff, and J.J. Wang Disruption of murine cardiac allograft acceptance by latent cytomegalovirus Am J Transplant 9 2009 42
52. S. Varani, G. Frascaroli, and D. Gibellini Impaired dendritic cell immunophenotype and function in heart transplant patients undergoing active cytomegalovirus infection Transplantation 79 2005 219
53. W. Tu, L. Potena, and P. Stepick-Biek T-Cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease Circulation 114 2006 1608
54. G. Gerna, D. Lilleri, and C. Fornara Monitoring of human cytomegalovirus-specific CD4+ and CD8+ t-cell immunity in patients receiving solid organ transplantation Am J Transplant 6 2006 2356
55. V.C. Emery Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation Rev Med Virol 11 2001 83
56. M. Vigan, T. Dengler, and M.F. Mattei Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study Transplant Infect Dis 12 2010 23
57. L. Demopoulos, M. Polinsky, and G. Steele Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials Transplant Proc 40 2008 1407
58. Potena L: Presented at: ISHLT 30th Anniversary Meeting and Scientific Sessions; April 2124, 2010; Chicago, IL. Abstract 474
59. L. Potena, C. Holweg, and C. Chin Acute rejection and cardiac allograft vascular disease Is reduced by suppression of subclinical cytomegalovirus infection Transplantation 82 2006 398
60. H.A. Valantine, H. Luikart, and R. Doyle Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation Transplantation 72 2001 1647
61. E. Ruttmann, C. Geltner, and B. Bucher Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation Transplantation 81 2006 1415
62. S.C. Jordan, A. Vo, and S. Bunnapradist Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients Transplantation 76 2003 631
63. M.R. Zamora Cytomegalovirus and lung transplantation Am J Transplant 4 2004 1219
64. J.D. Christie, L.B. Edwards, and P. Aurora The registry of the International Society for Heart and Lung Transplantation: Twenty-sixth official adult lung and heart-lung transplantation report2009 J Heart Lung Transplant 28 2009 1031
65. P.D. Shah, and J.F. McDyer Viral infections in lung transplant recipients Semin Respir Crit Care Med 31 2010 243
66. M.R. Zamora, R.D. Davis, and C. Leonard Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations Transplantation 80 2005 157
67. M.T. Parada, A. Alba, and C. Seplveda Bronchiolitis Obliterans Syndrome development in lung transplantation patients Transplant Proc 42 2010 331
68. M.R. Zamora Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation Transplant Infect Dis 3 2001 S49
69. P. Solidoro, D. Libertucci, and L. Delsedime Combined cytomegalovirus prophylaxis in lung transplantation: effects on acute rejection, lymphocytic bronchitis/bronchiolitis, and herpesvirus infections Transplant Proc 40 2008 2013
70. D. Weill, B.J. Lock, and D.L. Wewers Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction Am J Transplant 3 2003 492